An autologous CAR T‑cell therapy made from a patient’s T cells engineered ex vivo to express a chimeric antigen receptor recognizing a glioblastoma-associated surface antigen. Upon antigen engagement, CAR signaling activates the T cells, leading to cytokine release and perforin/granzyme-mediated cytotoxicity to lyse tumor cells. Dosed as multiple infusions (starting around 5×10^4 CAR+ T cells) with safety/PK-guided escalation.